Glucocorticoids (GC) are potent anti-inflammatory drugs widely used to induce remission in rheumatoid arthritis or to treat an acute flair-up in osteoarthritis.

Unfortunately, GC contribute to adverse events giving rise to metabolic syndromes such as diabetes and weight gain, leading sometimes to a high morbidity. Accordingly, we focus on new molecules, namely selective glucocorticoid receptor agonists (SEGRAs), with a better benefit/risk ratio compared to GC. Anti-inflammatory and anti-metabolic properties of SEGRAs are evaluated in vitro on human joint cells.

Interested in these projects? Drop us an email []. We are looking forward collaborating with you!